Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93892Research ArticleAntagonisty mineralokortikoidnykh retseptorov v klinicheskoy praktikeAndreevD. A-15052013155677028122021Copyright © 2013, Consilium Medicum2013[Герасимова Е.Н. Альдостерон в клинике внутренних болезней. Кардиология. 1961; 3: 92–4.][Simpson S.A, Tait J.F, Bush I.E. Secretion of a salt - retainig hormone by the mammalian adrenal cortex. The Lancet 1952; 260 (6727): 226–8.][Slater J.D.H. Aldosterone antagonism by 17-Spirolactosteroids. Postgrad Med J 1960; 36 (416): 399–407.][Hutchinson J.H, Porte G.A. Spirolactone inhibition of aldosterone induced nuclear RNA synthesis in toad urinary bladder. Res Comm Chem Path Pharm 1970; 1 (3): 363–9.][Smith W.G. The Lancet 1962; 280 (7261): 886.][Мухарлямов Н.А., Мареев В.Ю. Лечение хронической сердечной недостаточности. М., 1985.][Borghi С, Ambrosioni E. Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1996; 10 (3): 519–25.][The Merit Study Group. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000; 283 (10): 1295–302.][Pitt B. «Escape» of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9 (4): 145–9.][Borghi C et al. Evidence of a partial escape of renin - angiotensin - aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33 (9): 40–5.][Weber K.T, Villarreal D, Griffing G.T. Heart Failure: Pathophysiology, Aldosterone and Anti - aldosterone therapy. GD Searle & Co 1993.][The CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730–6.][Selye H. Protection by a steroid - spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960; 104 (7): 212–3.][The RALES Investigators. Effectiveness of spironolactone added to an angiotensin - converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78 (11): 902–7.][Bertram P et al. for The randomized aldactone evaluation study investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341 (10): 709–17.][Maron B.A, Leopold J.A. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010; 121 (7): 934–9.][Pitt B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 (14): 1309–21.][Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46 (3): 425–31.][Zannad F, Mc Murray J.J, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11–21.][ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–847.]